---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090086"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2026-08-04T12:05:12+00:00"
generated_at: "2026-08-04T12:10:27.641529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q2 revenue $261.3M (+30% YoY); EPS $1.28; reiterates FY guidance $1.0-1.04B

## Summary
- Q2 net revenue $261.3M, up 30% YoY; average patients 8,950 (+450).
- Net income $75.4M ($1.28 diluted EPS) vs $39.8M ($0.68) in Q2 2025.
- Reiterates 2026 WAKIX net revenue guidance of $1.0B-$1.04B.
- BP-205 Phase 1 SAD data favorable; Phase 1b in sleep-deprived volunteers starts Q3; Phase 2 mid-2027.
- Cash and investments $962.5M as of June 30, 2026.

## SEC filing metadata
- accession: 0001104659-26-090086
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2026-08-04T12:05:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/0001104659-26-090086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090086
- JSON: https://secwatch.observer/filing/0001104659-26-090086.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.